ITOS | iTeos Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.09 - 7.51
52 Week Range	7.09 - 18.75
Beta	1.28
Implied Volatility	723.36%
IV Rank	41.53%
Day's Volume	2,121,222
Average Volume	564,861
Shares Outstanding	36,533,900
Market Cap	271,081,538
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-07-24

Valuation
Profitability
Growth
Health
P/E Ratio	-2.36
Forward P/E Ratio	N/A
EPS	-3.14
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	157
Country	USA
Website	ITOS

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS's peers: ACHV, ALLO, ATAI, ATRA, CGEN, DBVT, CYBN, ICVX, MRTX, VECT, ANNX, GRCL, THRX, GLUE, DSGN, ERAS, APLS, TCRX, TERN, DAWN, ABOS, AMLX, MLTX, RVMD, BPMC, SANA, KYMR, MNMD, RCUS, WVE, ZNTL, ERNA, OABI

*Chart delayed

Analyzing fundamentals for ITOS we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see ITOS Fundamentals page.

Watching at ITOS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ITOS Technicals page.